bioAffinity Technologies' CyPath Lung featured at Cleveland Clinic symposium Apr 16

bioAffinity Technologies, Inc.

CyPath Lung test to be highlighted at invitation-only 'Advances in Early Lung Cancer Detection' symposium.
CMO Gordon Downie, MD, PhD, to serve on panel discussing lung nodule management.
Test has demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting early-stage lung cancer.
This marks the company's seventh invitation to present at the Cleveland Clinic symposium.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.